Market Access Editorial Support for Clinical Publications

In market access, the way clinical results are reported is just as crucial as the study design itself

Clinical evidence is essential for the successful adoption of medical technologies by clinicians, payers, and health technology assessment (HTA) bodies. However, due to tighter budgets and different regulatory pathways, the volume of evidence generated for medical technologies is often significantly lower than for pharmaceuticals. In this context, every published study becomes critically important.

In market access, the quality of clinical evidence is defined not only by the study design but also by the clarity and rigor of its presentation. Our extensive experience across European markets shows that valuable evidence is frequently downgraded due to suboptimal reporting - where key methodological details are missing or results are poorly presented.

At MTRC, we help close the gap between the clinical research output for medical devices and the evidence expectations of HTA and reimbursement authorities in Europe. We offer expert editorial support to refine clinical and health economic manuscripts, ensuring they meet the requirements of market access stakeholders. Additionally, we support the review and enhancement of clinical trial protocols to ensure methodological robustness aligned with reimbursement needs.

How does it work?

Our editorial support follows a structured approach to ensure clinical and economic publications meet the standards of market access stakeholders. The key steps are outlined below:

Scoping

The client shares the clinical study protocol or completed manuscript with our team. If needed, we conduct a scoping call to understand the context and objectives, including target countries, comparator technologies, and intended clinical indications for market access.

Review by MTRC

Our Health Economics and Outcomes Research (HEOR) team conducts a thorough review using MTRC’s internal quality standards. We focus on key methodological aspects, completeness of reporting according to international guidelines, and the specific requirements of major European HTA and reimbursement bodies such as NICE (UK), HAS (France), and IQWiG (Germany). Particular attention is given to statistical methods and subgroup analyses.

Feedback and Recommendations

All edits are tracked, and detailed comments or suggestions are included where appropriate. The review concludes with a debriefing call to present the findings, discuss recommended revisions, and provide guidance for improving the overall quality and market access relevance of the document.

Technological Coverage of Our Services

MTRC supports European market access and HEOR work for most medical technologies, including:

Implantable devices

Interventional procedures

Non-interventional procedures

In-Vitro diagnostics (IVD) tests

Medical aids

Our team has worked on hundreds of reimbursement/HEOR projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy, in-vitro diagnostic tests, companion diagnostic tests (CDx), medical aids, health apps, remote monitoring technologies, decision support systems, artificial intelligence (AI) technologies, amongst others.

Why Partner with MTRC?

Focused MedTech / IVD specialization

We focus on medical technologies, not broad life sciences. This matters because devices, diagnostics, procedures, software and care pathways face different access challenges than pharmaceuticals. Reimbursement, coding, tariffs, payer approval, HTA, evidence expectations and health economic arguments must be interpreted in the context of how the technology is actually used

Pan-European coverage from one specialist partner

Many market access advisors are country-specific. MTRC provides a consistent view across major European markets, helping clients compare countries, identify access differences and avoid fragmented local advice

Integrated MedTech access, evidence and economics support

MTRC supports clients across the full European MedTech access journey - from reimbursement coding, pathway analysis and strategy to evidence synthesis, value dossiers, health economic models, and HEOR implementation support

Unique access intelligence asset

MTRC’s project work is supported by continuous monitoring of reimbursement, payer, HTA and market access developments. Through MTRC Access Intelligence, clients benefit from structured insight into changes that may affect launch, evidence, value and portfolio decisions

Credibility from accumulated experience, thought leadership and industry engagement

MTRC’s advice is grounded in 1,000+ European MedTech market access projects and a strong body of thought leadership, including “Gateway to Europe”, the first dedicated book on European market access for medical technologies, proprietary market access methodologies, the MTRC Training Program, numerous white papers, and analytical newsletters. MTRC is a member of ABHI, the UK’s leading health technology industry association, strengthening our connection to the wider MedTech ecosystem

One of the Largest Specialist MedTech Access Teams Globally

MTRC is a focused team of around 30 people, making us one of the largest specialist MedTech market access consulting teams globally. Unlike firms that rely on country freelancers or generalist consultants, we have built an in-house European MedTech access platform. With over 60% of our team trained as physicians, we are able to quickly understand clinical and procedural complexity and translate it into practical reimbursement, HTA, payer, and evidence implications

Certified quality-management system

MTRC is ISO 9001:2015 accredited by the United Kingdom Accreditation Service (UKAS). This reflects our commitment to structured processes, quality control and consistent delivery across complex multi-country projects.

Get insights from MTRC free analytical reports

Explore MTRC’s free analytical reports and white papers for guidance on aligning your clinical manuscripts with European reimbursement and HTA requirements.

Explore MTRC research papers:

Best Reporting Checklists for Studies of Medical Devices (Report #20)

Explore more white papers

MTRC in Numbers

Specialist European MedTech Access Expertise at Scale

Full-time employees

1,057

Projects

239

Clients

Regular clients from the top 30 med tech companies

34%

Of business comes from Small to Medium-sized Enterprises (SMEs)

Featured Publications

MTRC members and associated researchers have a proven track record with the publication of results of systematic literature reviews and health economic analyses. Some of the examples of our publications are presented below.

Borisenko O, Maslov A, Baka A, Anelli MC, Das L, Roscigno M, Conti A.

Utility of MpMRI and phi in detection of prostate cancer in Italy: a decision analytic modeling

Anticancer Research Abstracts of the 34th Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 2024(44): 4617-4661

Borisenko O, Maslov A, Baka A, Anelli MC, Das L, Terracciano D.

EE777 Diagnostic Pathways for Prostate Cancer in Italy: A Cost-Consequences Analysis

Value in Health 2024 Dec, Volume 27, Issue 12, S208

Moola S, Tyagi J, Miller M, Gudi N, Pettigrew S, Bhaumik S.

Interventions addressing maternal and child health among the urban poor and homeless: an overview of systematic reviews

J Med Econ. 2018 Jan 10:1-9.

Borisenko O, Colpan Z, Dillemans B, Funch-Jensen P, Hedenbro J, Ahmed R Ahmed.

Clinical Indications, Utilization and Funding of Bariatric Surgery in Europe

Obes Surg. 2015 Aug;25(8):1408-16.

All publications